NCT01676753: Phase 1b Dose De-escalation Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1|Phase 2
Drug Category: Serine-Threonine Kinase Inhibitor, Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 85 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Central nervous system (CNS) metastases; patients with CNS metastases that are stable would be eligible

Comments are closed.

Up ↑